Related Experiment Video
Updated: May 5, 2026
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Novel PROTACs with polyhedral alkanes as linkers for enhanced ALK degradation in drug-resistant NSCLC
Dongchen Chu1, Huijie Han1, Chaochun Wei2
1College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, PR China.
Abstract:
The challenge of overcoming drug-resistant mutations in Anaplastic Lymphoma Kinase (ALK), a critical driver of non-small cell lung cancer (NSCLC), remains a pressing clinical concern. This study introduces a novel approach by using polyhedral alkanes as linkers in PROTAC (Proteolysis Targeting Chimera) technology to address resistance mechanisms. Unlike conventional chain-like or planar linkers, five novel ALK-targeting PROTACs (BL-1-BL-5) featuring structurally unique polyhedral alkanes (cubane, homocubane, adamantane, D3-trihomocubane and norbornene) were designed and synthesized through innovative HAPOD trail and organic synthesis methodologies. Comprehensive in vitro evaluations revealed remarkable antiproliferative activity across all derivatives, with BL-5 (norbornene as linker) demonstrating exceptional potency (IC₅₀ = 36.21 nM) against H3122 cells, surpassing both reference SIAIS164018 (BB-1, IC₅₀ = 78.93 nM) and Brigatinib (IC₅₀ = 44.83 nM). Western blot assay confirmed that BL-5 effectively degraded ALK at 100 nM concentration while effectively inhibiting ALK phosphorylation. Notably, BL-5 exhibited superior efficacy against Ba/F3 cells with the ALK G1202R resistance mutation (IC50 = 118.86 nM) compared to BB-1 (IC₅₀ = 126.41 nM). MD simulations provided critical insights, revealing that the BL-1, BL-4 and BL-5 significantly enhanced the ternary complex stability compared to traditional linkers. These findings establish the polyhedral alkanes as novel linkers in PROTAC design, with BL-5 emerging as a particularly promising candidate for targeting ALK.
Insights
Novel polyhedral alkane linkers in Proteolysis Targeting Chimeras (PROTACs) effectively target Anaplastic Lymphoma Kinase (ALK) in non-small cell lung cancer, overcoming drug resistance. BL-5 demonstrated superior potency and ALK degradation.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Drug-resistant Anaplastic Lymphoma Kinase (ALK) mutations are a major challenge in non-small cell lung cancer (NSCLC) treatment.
- Proteolysis Targeting Chimera (PROTAC) technology offers a promising strategy to degrade target proteins, including ALK.
Purpose of the Study:
- To design and synthesize novel ALK-targeting PROTACs utilizing polyhedral alkanes as linkers.
- To evaluate the efficacy of these novel PROTACs against ALK-driven NSCLC, including drug-resistant mutations.
Main Methods:
- Synthesis of five novel ALK-targeting PROTACs (BL-1-BL-5) featuring polyhedral alkane linkers (cubane, homocubane, adamantane, D3-trihomocubane, norbornene).
- In vitro antiproliferative assays against NSCLC cell lines.
- Western blot analysis for ALK degradation and phosphorylation.
- Molecular Dynamics (MD) simulations to assess ternary complex stability.
Main Results:
- All synthesized PROTACs exhibited significant antiproliferative activity.
- BL-5, featuring a norbornene linker, showed superior potency (IC50 = 36.21 nM) against H3122 cells compared to references.
- BL-5 effectively degraded ALK and inhibited its phosphorylation, and demonstrated superior efficacy against the ALK G1202R resistance mutation.
- MD simulations indicated enhanced ternary complex stability with polyhedral alkane linkers (BL-1, BL-4, BL-5).
Conclusions:
- Polyhedral alkanes represent a novel and effective class of linkers for PROTAC design.
- BL-5 is a highly promising candidate for targeting ALK in NSCLC, particularly in cases of drug resistance.
- This study provides a new avenue for developing next-generation ALK inhibitors.
